Cover Image
市場調查報告書

分子診斷:癌症診斷、產前檢查市場特性、擴大趨勢相關考察

Molecular Diagnostics: An Insight to Rising Markets and Trends in Cancer and Prenatal Technologies

出版商 Insight Pharma Reports 商品編碼 295746
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
Back to Top
分子診斷:癌症診斷、產前檢查市場特性、擴大趨勢相關考察 Molecular Diagnostics: An Insight to Rising Markets and Trends in Cancer and Prenatal Technologies
出版日期: 2014年02月15日 內容資訊: 英文 122 Pages
簡介

本報告提供全球的癌症(肺癌、乳癌、血液癌症(白血病、淋巴瘤))診斷及遺傳基因資訊、產前檢查用技術的開發情形、及相關企業概要、最新產品信息、經營謀略、今後的分子診斷相關機會、課題的相關調查結果等,為您概述為以下內容。

摘要整理

第1部分 簡介、市場背景

第1部分 本報告概要

第2章 市場趨勢與適用性

第2部分 癌症診斷

第3章 肺癌症

  • 疾病的種類
  • 風險要素
  • 發病數量
  • 症狀與早期發現
  • 標靶治療

第4章 乳癌

第5章 GeneCentric

  • 企業的背景
  • Lung Subtype Platform (LSP)
  • Hypoxia Signature Platform
  • GeneCentric的未來展望
  • 採訪(Myla Lai-Goldman)

第6章 甲狀腺癌症

第7章 Veracyte

  • 企業的背景
  • Afirma Thyroid FNA Analysis
  • 檢驗
  • 競爭上的優勢
  • 今後的成長計劃
  • 採訪(Bonnie Anderson)

第8章 血液系統的癌症

  • 白血病
  • 惡性淋巴腫瘤
  • 古典的何杰金氏病
  • 結節性淋巴細胞豐富型何杰金氏淋巴瘤
  • 非何杰金氏淋巴瘤

第9章 Adaptive Biotechnologies Corporation

  • 企業的背景
  • ClonoSEQ
  • 檢驗
  • 改善的領域
  • 競爭上的優勢
  • 今後的著重領域
  • 採訪(Chad Robins)

第3部分 遺傳基因資訊和產前診斷

第10章 遺傳基因資訊和產前檢查

  • 遺傳基因資訊
  • 產前檢查
    • 序列基礎的無細胞DNA檢驗
    • 胎兒細胞的分離

第11章 GenePeeks

  • 企業的背景
  • 取得專利的技術
  • 流程功能的辦法
  • 檢驗
  • 正確性和靈敏度
  • 改善的領域
  • 競爭上的優勢
  • 今後的應用領域
  • 採訪(Anne Morriss)

第12章 Verinata Health

  • 企業的背景
  • The verifi® prenatal test
  • 臨床上的檢驗與醫療費給付
  • 客戶的反應

第13章 檢驗的詳細

第4部分 調查對象的人口組成

第14章 調查結果

  • 調查受訪者的人口組成
  • 調查領域
  • 今後有前途的技術
  • 今後面臨的課題

第5部分 企業目錄

相關調查

關於Cambridge Healthtech Institute

圖表一覽

目錄

Molecular Diagnostics: An Insight to Rising Markets and Trends in Cancer and Prenatal Technologie covers market research, relevant disease background, and a number of rising technologies available to physicians and clinicians in the cancer and prenatal space. This report focuses on market background of the areas that are covered, including lung, breast, thyroid and blood cancers (specifically leukemia and lymphoma), as well as pre-conception genetic information and prenatal diagnostics.

Included in this Report:

  • Cancer diagnostics companies interviewed include: GeneCentric, Veracyte, Adaptive Biotechnologies
  • Genetic and prenatal diagnostics research companies including GenePeeks and Verinata Health
  • Comprehensive coverage of survey results (n=123) from the various companies and researchers working in molecular diagnostics.
  • A company directory which was created for this report. This includes several seasoned and emerging companies, their areas of focus, and the status of their technologies.

Table of Contents

Executive Summary

PART I: Introduction and Market Background

CHAPTER 1: The Focus of This Report

CHAPTER 2: Market Trends and Adaptability

  • Lung cancer diagnostics market growth
  • Breast cancer diagnostics market growth
  • Thyroid cancer diagnostics market growth
  • Blood cancer diagnostics market growth
  • Prenatal diagnostics market growth

PART II: Cancer Diagnostics

CHAPTER 3: Lung Cancer

  • Types of lung cancer
  • Risk factors
  • Incidence
  • Symptoms and early detection
  • Targeted therapies

CHAPTER 4: Breast Cancer

  • Types of breast cancer
  • Risk factors
  • Incidence
  • Symptoms and early detection
  • Treatments for breast cancer

CHAPTER 5: GeneCentric

  • Company background
  • Lung Subtype Platform (LSP)
  • Hypoxia Signature Platform
  • GeneCentric outlook
  • Interview with Myla Lai-Goldman
    • Company background
    • Platforms
    • Future outlook

CHAPTER 6: Thyroid Cancer

  • Types
  • Risk
  • Symptoms and early detection
  • Therapeutic options

CHAPTER 7: Veracyte

  • Company background
  • Afirma Thyroid FNA Analysis
  • Validation
  • Competitive advantage
  • Future growth plans
  • Interview with Bonnie Anderson
    • Company background
    • Afirma Thyroid FNA Analysis
    • Competitive advantage
    • Challenges encountered
    • Future improvements

CHAPTER 8: Blood-Based Cancers

  • Leukemia
    • Types
    • Risk factors, symptoms and early detection
    • Therapeutic options
  • Lymphoma
    • Types
  • Classic Hodgkin disease
  • Nodular lymphocyte predominant Hodgkin disease
  • Non-Hodgkin lymphoma
    • Risk factors
    • Symptoms and therapeutic options

CHAPTER 9: Adaptive Biotechnologies Corporation

  • Company background
  • ClonoSEQ
  • Validation
  • Areas of improvement
  • Competitive advantage
  • Future endeavors
  • Interview with Chad Robins
    • Company background
    • ClonoSEQ
    • Areas of improvement
    • Challenges encountered
    • Competitive advantage
    • Future endeavors

PART III: Genetic Information and Prenatal Diagnostics

CHAPTER 10: Genetic Information and Prenatal Testing

  • Genetic information
  • Prenatal testing
    • Sequence-based cell-free DNA testing
    • Fetal cell isolation

CHAPTER 11: GenePeeks

  • Company background
  • Patented technology
  • How does the process work?
  • Validation
  • Accuracy and sensitivity
  • Areas of improvement
  • Competitive advantage
  • Future applications
  • Interview with Anne Morriss
    • Company background
    • Patented technology
    • Competitive advantage
    • Areas of improvement and future outlook

CHAPTER 12: Verinata Health

  • Company background
  • The verifi® prenatal test
  • Clinical validation and reimbursement
  • Customer feedback

CHAPTER 13: Testing Specifications

PART IV: Survey Demographics

CHAPTER 14: Survey Results

  • Survey demographics
  • Areas of study
  • Rising technologies
  • Challenges encountered

PART V: Company Directory

References

About Cambridge Healthtech Institute

Back to Top